Amylyx Pharmaceuticals (NASDAQ: AMLX) CFO Frates logs tax sale filing

Rhea-AI Filing Summary

Amylyx Pharmaceuticals, Inc. Chief Financial Officer James M. Frates reported an automatic sale of common stock. On January 6, 2026, he sold 3,326 shares of Amylyx common stock at a weighted average price of $11.1106 per share. According to the filing, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units, and the sale was not at his discretion.

After this transaction, Frates directly beneficially owned 177,104 shares of Amylyx common stock. He also had indirect holdings through trusts, including 100,000 shares held by the JAMES M. FRATES 2025 GRAT No. 1 and additional blocks of 15,459 shares and 11,072 shares in other family trusts. For these trust holdings, he serves as trustee and disclaims beneficial ownership except to the extent of any pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FRATES JAMES M

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S(1)		3,326(1)	D	$11.1106(2)	177,104	D
Common Stock								100,000(3)	I	By Trust(3)
Common Stock								15,459	I	By Trust(4)
Common Stock								11,072	I	By Trust(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.99 to $11.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

3. On December 15, 2025, the Reporting Person contributed 100,000 shares of Issuer common stock to a grantor retained annuity trust for no consideration. Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

4. Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

5. Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

	/s/ Joshua B. Cohen, as Attorney in Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AMLX CFO James M. Frates report?

James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported selling 3,326 shares of common stock on January 6, 2026, as shown in a Form 4 filing.

At what price were the Amylyx (AMLX) shares sold by the CFO?

The 3,326 shares of Amylyx common stock were sold at a weighted average price of $11.1106 per share, with individual trade prices ranging from $10.99 to $11.16.

Why did Amylyx CFO James M. Frates sell 3,326 shares?

The filing states the 3,326 shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, and that these sales were automatic and not at his discretion.

How many Amylyx (AMLX) shares does the CFO hold after the reported sale?

Following the reported transaction, James M. Frates directly beneficially owned 177,104 shares of Amylyx common stock, according to the Form 4.

What indirect Amylyx share holdings does James M. Frates report through trusts?

The Form 4 lists 100,000 shares held by the JAMES M. FRATES 2025 GRAT No. 1, and additional trust holdings of 15,459 shares and 11,072 shares. Frates serves as trustee and disclaims beneficial ownership of these shares except to the extent of any pecuniary interest.

Was the 100,000-share trust position in AMLX created by a prior transfer?

Yes. The filing explains that on December 15, 2025, James M. Frates contributed 100,000 shares of Amylyx common stock to a grantor retained annuity trust for no consideration, which now holds those shares.